NV-SPHERICAM
18.4.2016 02:01:51 CEST | Business Wire | Press release
Sphericam 2, the world’s first 360˚ VR camera capable of self-stitching and livestreaming 4K video in real-time will start shipping this summer. Full-scale production is scheduled to begin at a U.S. production facility this July following a successful Kickstarter campaign and new $5 million investment from China’s Kingnet Technologies.
“The Sphericam 2 is like no other camera on the market. With a global shutter capable of shooting at 60 frames per second and the ability to self-stitch and livestream 4K video, it sets a new bar for performance. It’s also incredibly compact, roughly the size of a baseball. We designed the camera with professionals in mind which is why we’re thrilled use our presence at NAB to announce it will be available this summer” says Jeffrey Martin, Sphericam founder and CEO. The National Association of Broadcasters trade show in Las Vegas marks the first time the public will be able to view a live demo of the Sphericam 2.
The camera was first announced on Kickstarter in 2015 where it received backing of $450,000, more than four times the initial target.
“Our Kickstarter backers and pre-order customers will be the first to receive the Sphericam 2 once it ships. We also have large media and technology companies eager to start using the camera. The recent investment from Kingnet helps us not only accelerate our production timetable but to broaden our product and service portfolio,” says Martin.
The Shanghai-based online and mobile gaming company Kingnet is investing $5 million as part of a new strategic focus on VR content.
“We invested in Sphericam because it’s clear that it’s more than just a VR hardware company,” Wang Yue, CEO of Kingnet Technologies. “Sphericam is building a bridge between people’s real-world experiences and the VR space. The Sphericam 2 allows people to capture and share 360˚ video in a format that’s perfect for today’s virtual reality headsets and this is only the beginning.
Sphericam will be important part of Kingnet’s “platform+content+VR” strategy far into the future.”
The Sphericam 2 is available for pre-order at a cost of $2500.
Visit us at NAB 2016, Las Vegas, USA
April 16th – 21st
Booth N8022
North Hall, VR Pavilion
About Sphericam
Founded by American photographer Jeffrey Martin along with Dutch hardware specialist Servaes Joordens and software specialist Poppo Wit in 2014, Sphericam is dedicated to building groundbreaking 360˚ cameras to create original content for virtual reality platforms and interactive online media. The company’s newest product, called Sphericam 2, is an immersive capture device capable of self-stitching and streaming live 4K video at 60 frames per second. The company has offices in Prague, Haarlem, Haaren and Ljubljana.
Images and example 360˚ video content: http://bit.do/sphericam
View source version on businesswire.com: http://www.businesswire.com/news/home/20160417005021/en/
Contact:
Media contact
US:
Gaja Zornada
gaja@sphericam.com
+38-64-1215-430
+1-401-3-430-430
or
George
Krieger
press@sphericam.com
+1-831-717-7214
or
Europe:
Marc
Rettig
marc.Rettig@nelsonbostockunlimited.com
T
+44-7814-794253
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom